Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 15, 2024, discloses the vesting of Deferred Annual Bonus Plan (DABP) awards granted in 2021 to Persons Discharging Managerial Responsibilities (PDMRs). The three-year restricted period for these awards concluded on February 12, 2024. The filing details the subsequent exercise of nil-cost options and the sale of Ordinary Shares and American Depositary Shares (ADSs) to meet tax liabilities.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation transactions. Key market data points provided include:
- Ordinary Share Closing Price (Feb 12, 2024): £16.264
- ADS Closing Price (Feb 12, 2024): $41.07
- Transaction Date: February 12, 2024
Material Changes and Transaction Details
The filing reports a series of transactions involving the vesting of awards and immediate sales to cover tax obligations. No material changes to the company's business operations or financial position are reported. The specific transactions are summarized below:
| Executive | Position | Instrument | Vesting Volume | Sale Volume (Tax) | Sale Price |
|---|---|---|---|---|---|
| Emma Walmsley | CEO | Ordinary Shares | 52,435 | 24,682 | £16.5180 |
| Dr Hal Barron | Non-Executive Director | ADSs | 27,796 | 14,941 | $41.0648 |
| Diana Conrad | Chief People Officer | Ordinary Shares | 7,600 | 4,083 | £16.5104 |
| James Ford | SVP, Group General Counsel | Ordinary Shares | 9,157 | 4,319 | £16.5056 |
| Sally Jackson | SVP, Global Communications | Ordinary Shares | 4,627 | 2,183 | £16.5238 |
| Luke Miels | Chief Commercial Officer | Ordinary Shares | 14,209 | 166 | £16.5020 |
| David Redfern | President, Corporate Development | Ordinary Shares | 11,169 | 5,263 | £16.5152 |
| Regis Simard | President, Global Supply Chain | Ordinary Shares | 8,414 | 3,969 | £16.4822 |
| Phil Thomson | President, Global Affairs | Ordinary Shares | 6,532 | 3,081 | £16.4906 |
| Deborah Waterhouse | CEO, ViiV Healthcare | Ordinary Shares | 13,426 | 6,327 | £16.5186 |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, or specific risk factors. The transactions were conducted in accordance with the shareholder-approved 2017 Remuneration Policy and the DABP rules, which mandate a three-year restricted period for bonus deferrals. Dividends accrued on the awards during this period.
Investor Verification Checklist
- Verify the total number of shares sold to meet tax liabilities versus the total number of shares vested to assess net retention by executives.
- Confirm the alignment of these transactions with the 2017 Remuneration Policy and the specific vesting schedule of the 2021 DABP awards.
- Review the market price at the time of sale (£16.264 for Ordinary Shares, $41.07 for ADSs) against the transaction prices to ensure execution at fair market value.
- Note that this filing contains no operational or financial performance data; refer to Form 20-F or quarterly reports for corporate metrics.